Literature DB >> 29663947

Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis.

Gustavo E Velásquez1, Geraint R Davies2, Carole D Mitnick3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29663947      PMCID： PMC5940349          DOI： 10.5588/ijtld.18.0210

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  9 in total

1.  Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

Authors:  G Pillai; P B Fourie; N Padayatchi; P C Onyebujoh; H McIlleron; P J Smith; G Gabriels
Journal:  Int J Tuberc Lung Dis       Date:  1999-11       Impact factor: 2.373

2.  Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

Authors:  Emmanuel Chigutsa; Jotam G Pasipanodya; Marianne E Visser; Paul D van Helden; Peter J Smith; Frederick A Sirgel; Tawanda Gumbo; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

3.  Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Authors:  R E Aarnoutse; G S Kibiki; K Reither; H H Semvua; F Haraka; C M Mtabho; S G Mpagama; J van den Boogaard; I M Sumari-de Boer; C Magis-Escurra; M Wattenberg; J G M Logger; L H M Te Brake; M Hoelscher; S H Gillespie; A Colbers; P P J Phillips; G Plemper van Balen; M J Boeree
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.

Authors:  A Jindani; G Borgulya; I Westermann de Patiño; T Gonzales; R A de Fernandes; B Shrestha; D Atwine; M Bonnet; M Burgos; F Dubash; N Patel; A M Checkley; T S Harrison; D Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2016-06       Impact factor: 2.373

5.  Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Authors:  Jotam G Pasipanodya; Helen McIlleron; André Burger; Peter A Wash; Peter Smith; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2013-07-29       Impact factor: 5.226

6.  Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.

Authors:  C A Peloquin; G E Velásquez; L Lecca; R I Calderón; J Coit; M Milstein; E Osso; J Jimenez; K Tintaya; E Sanchez Garavito; D Vargas Vasquez; C D Mitnick; G Davies
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Authors:  Martin J Boeree; Andreas H Diacon; Rodney Dawson; Kim Narunsky; Jeannine du Bois; Amour Venter; Patrick P J Phillips; Stephen H Gillespie; Timothy D McHugh; Michael Hoelscher; Norbert Heinrich; Sunita Rehal; Dick van Soolingen; Jakko van Ingen; Cecile Magis-Escurra; David Burger; Georgette Plemper van Balen; Rob E Aarnoutse
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

8.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Authors:  Martin J Boeree; Norbert Heinrich; Rob Aarnoutse; Andreas H Diacon; Rodney Dawson; Sunita Rehal; Gibson S Kibiki; Gavin Churchyard; Ian Sanne; Nyanda E Ntinginya; Lilian T Minja; Robert D Hunt; Salome Charalambous; Madeleine Hanekom; Hadija H Semvua; Stellah G Mpagama; Christina Manyama; Bariki Mtafya; Klaus Reither; Robert S Wallis; Amour Venter; Kim Narunsky; Anka Mekota; Sonja Henne; Angela Colbers; Georgette Plemper van Balen; Stephen H Gillespie; Patrick P J Phillips; Michael Hoelscher
Journal:  Lancet Infect Dis       Date:  2016-10-26       Impact factor: 25.071

9.  Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.

Authors:  R Court; M T Chirehwa; L Wiesner; B Wright; W Smythe; N Kramer; H McIlleron
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 2.373
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.